for Patients Living with Serious Rare Conditions
VectivBio AG is a global biotechnology company committed to making a difference in the lives of patients
suffering from serious rare conditions.
We are assembling a best-in-disease pipeline in rare diseases, with a leading program aimed at patients living with Short Bowel Syndrome.
We are headquartered in Basel (Switzerland). We also have business operations in the New York area.
News & Media
Nov 4, 2020
VectivBio Strengthens Business Development Capabilities with Key Appointments
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development. Dr. Holland will be based in Switzerland and Dr. Venugopal will be based in the U.S., further expanding the company’s global reach.